Citatuzumab bogatox

Last updated August 26, 2025

Citatuzumab bogatox
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	TACSTD1
Clinical data
ATC code	none
Identifiers
CAS Number	945228-49-9 ^N
ChemSpider	none
UNII	23J303Z5CA
Chemical and physical data
Formula	C₃₄₅₅H₅₃₇₁N₉₂₁O₁₀₆₀S₁₈
Molar mass	77348.44 g·mol⁻¹
^NY (what is this?) (verify)

Citatuzumab bogatox (VB6-845) is a monoclonal antibody Fab fragment fused with bouganin,^[1] a ribosome inactivating protein from the plant Bougainvillea spectabilis.^[2] It has undergone preclinical development for the treatment of ovarian cancer and other solid tumors.^[3]

References

↑ Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M (2018). "Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update". Current Cancer Drug Targets. 18 (9): 857–868. doi:10.2174/1568009618666180102102311. PMID 29295696.
↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
↑ "VB6-845". Viventia Biotech Inc. Archived from the original on 29 March 2010.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab ^§ Amivantamab Ascrinvacumab ^§ Atezolizumab (+hyaluronidase) Balstilimab ^† Botensilimab Cixutumumab ^§ Conatumumab ^§ Cosibelimab Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin Enoticumab ^§ Figitumumab ^§ Flanvotumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Linvoseltamab Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Nivolumab ^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pembrolizumab ^# Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Sugemalimab Tarextumab ^§ Tisotumab vedotin Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Votumumab ^§ Zalutumumab ^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab ^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ecromeximab ^§ Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab ^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab ^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Datopotamab deruxtecan Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab Emibetuzumab ^§ Enoblituzumab ^§ Epcoritamab Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab ^§ Inotuzumab ozogamicin Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Naxitamab Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Odronextamab Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Penpulimab Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan Sibrotuzumab ^§ Simtuzumab ^§ Sofituzumab vedotin ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab ^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab ^§
Chimeric + humanized	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.